METHOD TO TREAT MAMMARY GLAND CANCER
medicine, oncology. SUBSTANCE: method deals with nonoperable patients and suggests to apply as a first treatment stage 4-7 injections paratumorally and into soft tissues at lymph outflow route using the following preparations, ml: 0.5%-richlocaine solution, 10; metotrexate, 5-10 mg; diclophenak solu...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English |
Published |
20.01.2002
|
Edition | 7 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | medicine, oncology. SUBSTANCE: method deals with nonoperable patients and suggests to apply as a first treatment stage 4-7 injections paratumorally and into soft tissues at lymph outflow route using the following preparations, ml: 0.5%-richlocaine solution, 10; metotrexate, 5-10 mg; diclophenak solution/injection separately, 3; in a day, then at no intervals antitumor chemopreparations should be injected at standard course doses upon autoblood together with 50 mg richlocaine upon autoblood thrice weekly, separately, subsequently, for 2 wk, then the courses of autohemochemotherapy along with richlocaine injection should be repeated after a 2- week-long interval without any preliminary injection of preparations paratumorally and into soft tissues at lymph outflow route out of the mammary gland. EFFECT: higher efficiency of therapy, increased immunomodulating effect, improved chemotherapy tolerance due to decreased body toxic reactions, improved life quality in nonoperable patients at treating local and disseminated mammary gland cancer (III-IV stages) by cytostatic preparations. 3 ex, 8 tbl, 10 dwg |
---|---|
Bibliography: | Application Number: RU20000106822 |